Barclays’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-100
Closed -$4K – 6696
2019
Q3
$4K Sell
100
-900
-90% -$35.9K ﹤0.01% 6483
2019
Q2
$43K Buy
+1,000
New +$42.5K ﹤0.01% 6168
2018
Q4
– Sell
-500
Closed -$25K – 7230
2018
Q3
$25K Hold
500
– – ﹤0.01% 6399
2018
Q2
$16K Sell
500
-164,500
-100% -$5.68M ﹤0.01% 6304
2018
Q1
$5.14M Buy
165,000
+139,800
+555% +$4.98M ﹤0.01% 1619
2017
Q4
$1.15M Sell
25,200
-82,700
-77% -$3.28M ﹤0.01% 2979
2017
Q3
$4.05M Buy
107,900
+106,700
+8,892% +$4.29M ﹤0.01% 1701
2017
Q2
$57K Sell
1,200
-4,300
-78% -$200K ﹤0.01% 5275
2017
Q1
$251K Buy
+5,500
New +$238K ﹤0.01% 4088
2015
Q3
– Sell
-53,900
Closed -$3.77M – 6985
2015
Q2
$3.77M Buy
+53,900
New +$4.24M ﹤0.01% 1722
2014
Q3
– Sell
-2,000
Closed -$182K – 7776
2014
Q2
$182K Hold
2,000
– – ﹤0.01% 4907
2014
Q1
$138K Buy
+2,000
New +$136K ﹤0.01% 5148
2013
Q3
– Sell
-10,800
Closed -$313K – 7553
2013
Q2
$313K Hold
10,800
– – ﹤0.01% 4735

Other funds holding PCRX

Barclays's PCRX Position: Q3 2026 in Review

Barclays increased its Pacira BioSciences (PCRX) stake by 15% in Q3 2026, buying an estimated $1.15M and bringing the position to 355,514 shares worth $8.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

Barclays first reported a position in PCRX in Q2 2013 and has held it in 54 quarters since. The position peaked at $12.3M in Q1 2017. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Barclays held 355,514 shares of Pacira BioSciences worth $8.91M as of Q3 2026.
  • Barclays bought 45,325 Pacira BioSciences shares in Q3 2026, an estimated $1.15M.
  • Pacira BioSciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1708 holding.
  • Barclays first reported a position in Pacira BioSciences in Q2 2013 and has held it in 54 quarters since.
  • Barclays's Pacira BioSciences position peaked at $12.3M in Q1 2017.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.